Rights & Society
Lung Cancer: New Treatment Approved in the EU
The European Medicines Agency (EMA) has recommended granting marketing authorization for Imdylltra (tarlatamab) as a monotherapy treatment for adults with relapsed extensive-stage small cell lung cancer in the EU. This recommendation offers a new therapeutic option for patients with limited treatment choices. The positive opinion is based on clinical trial data demonstrating the efficacy and safety of tarlatamab. The decision now goes to the European Commission for formal approval.
New treatment offers hope for relapsed lung cancer patients in EU.